Nikolai Naoumov
Nikolai V. Naoumov (born 1952) is a British Bulgarian physician-scientist, and Professor of Hepatology at University College London, who has contributed to the understanding and management of liver diseases throughout his career in clinical/academic research and drug development..[1]
Career
Nikolai Naoumov’s career in liver diseases started in 1979 when he was appointed as assistant-professor at the Department of Gastroenterology, Medical Academy, Sofia. In Bulgaria, he set up the first specialised laboratory for molecular diagnosis of hepatitis viruses; described the first cases of hepatitis Delta virus-induced liver disease[2]; published the first textbook on abdominal ultrasound in "The echographic diagnosis in internal medicine"[3], and was appointed as Associate Professor in liver diseases at the Medical Academy, Sofia. During his postgraduate training, he was awarded research fellowships from The Wellcome Trust (UK): 1981-83 (liver immunology); 1986-87 (molecular biology & liver pathology); 1990 (liver immunology), all three fellowships were held at the Institute of Liver Studies, King's College London. In 1991, he joined the Institute of Liver Studies, King’s College London, leading a research group with projects dedicated to hepatitis B and hepatitis C studies. In 1996, he was appointed as senior lecturer at University College London (UCL) and honorary consultant physician at UCL Hospitals. Nikolai Naoumov led the viral hepatitis clinical service, as well as a research group at the Institute of Hepatology and in 2005 was appointed as Professor of Hepatology at UCL.[4] In Professor Naoumov took the role of Global Head, Therapeutic Hepatology and Transplantation at Novartis, where he retired in 2021.[5]
Professional affiliations and roles
Nikolai Naoumov is Fellow of the Royal College of Physicians and the Royal College of Pathologists (UK). He is also Senior Fellow of the Association of Physicians of Great Britain and Ireland[6] and was elected as Fellow of the American Association for the Study of Liver Disease (AASLD). Since 2016, Naoumov serves as Trustee and Board Member of the Swiss Liver Research Foundation, Bern [7]. He has also served as Trustee and later Scientific Advisor to the Foundation for Liver Research, London (2007-2020); President of the International Medical Club; and Member of the Scientific Committee of the European Association for the Study of Liver (EASL) (1991-1994).[8] Naoumov serves in multiple advisory boards, for InSphero [9], Ciclofilin Pharmaceuticals [10] and Hepion Pharmaceuticals.[11] Naoumov has served as Editor for Liver diseases of the European Journal of Clinical Investigation, Associate Editor of the Journal of Hepatology, and special section Editor of Journal of Hepatology.[12]
Research
Nikolai Naoumov’s research integrates immunology, molecular biology and translational medicine in more than 300 peer reviewed publications[13]. Naoumov's main areas of expertise and key contributions are in hepatitis B – immunology and novel therapies,[14] [15] [16]; hepatitis C,[17]; liver transplantation for viral liver diseases [18]; development of investigational drugs [19] [20]; and digital pathology, particularly for quantitative assessment of liver fibrosis [21]
References
- ↑ "University College London".
- ↑ Naoumov, N. V.; Gueorgiev, A.; Ognyanov, M.; Maleev, A. (1986). "Infection with hepatitis delta virus in patients with fulminant hepatitis B and chronic HBsAg carriers in Bulgaria". Hepato-Gastroenterology. 33 (2): 49–51. PMID 3721387.
- ↑ The echographic diagnosis in internal medicine”. I Tomov and N Naoumov, Sofia 1992, ISBN 954-420-011-8
- ↑ "People 2005-2006". 2 July 2018.
- ↑ "University College London".
- ↑ "Fellows Directory - AoPGBI". 29 August 2022.
- ↑ "Swissliver foundation".
- ↑ "ILC 2021 Basic Science Seminar".
- ↑ "InSphero Further Strengthens Scientific Advisory Board for Liver Diseases by Appointing Professor Nikolai Naoumov - InSphero". 9 February 2022.
- ↑ "Ciclofilin Pharmaceuticals Welcomes Dr. Nikolai Naoumov to Its Scientific Advisory Board" (Press release). 4 February 2016.
- ↑ "Nikolai Naoumov, M.D., Ph.D. – Hepion Pharmaceuticals".
- ↑ https://www.journal-of-hepatology.eu/article/S0168-8278(05)00193-5/pdf
- ↑ "Google Scholar".
- ↑ Rossol, S.; Marinos, G.; Carucci, P.; Singer, M. V.; Williams, R.; Naoumov, N. V. (1997). "Interleukin-12 induction of Th1 cytokines is important for viral clearance in chronic hepatitis B". The Journal of Clinical Investigation. 99 (12): 3025–3033. doi:10.1172/JCI119498. PMC 508155. PMID 9185527.
- ↑ Neumann, Avidan U.; Phillips, Sandra; Levine, Idit; Ijaz, Samreen; Dahari, Harel; Eren, Rachel; Dagan, Shlomo; Naoumov, Nikolai V. (2010). "Novel Mechanism of Antibodies to Hepatitis B Virus in Blocking Viral Particle Release from Cells†". Hepatology. 52 (3): 875–885. doi:10.1002/hep.23778. PMC 3086357. PMID 20593455.
- ↑ Phillips, Sandra; Chokshi, Shilpa; Riva, Antonio; Evans, Alexander; Williams, Roger; Naoumov, Nikolai V. (2010). "CD8+ T Cell Control of Hepatitis B Virus Replication: Direct Comparison between Cytolytic and Noncytolytic Functions". The Journal of Immunology. 184 (1): 287–295. doi:10.4049/jimmunol.0902761. PMID 19949099.
- ↑ Naoumov, N. V.; Petrova, E. P.; Thomas, M. G.; Williams, R. (1998). "Presence of a newly described human DNA virus (TTV) in patients with liver disease". Lancet. 352 (9123): 195–197. doi:10.1016/S0140-6736(98)04069-0. PMID 9683209.
- ↑ Naoumov, Nikolai V.; Lopes, A.Ross; Burra, Patrizia; Caccamo, Lucio; Iemmolo, Rosa M.; De Man, Robert A.; Bassendine, Margaret; O'Grady, John G.; Portmann, Bernard C.; Anschuetz, Gaya; Barrett, Catherine A.; Williams, Roger; Atkins, Mark (2001). "Randomized trial of lamivudine versus hepatitis B immunoglobulin for long-term prophylaxis of hepatitis B recurrence after liver transplantation". Journal of Hepatology. 34 (6): 888–894. doi:10.1016/S0168-8278(01)00039-3. PMID 11451173.
- ↑ Liaw, Y. F.; Gane, E.; Leung, N.; Zeuzem, S.; Wang, Y.; Lai, C. L.; Heathcote, E. J.; Manns, M.; Bzowej, N.; Niu, J.; Han, S. H.; Hwang, S. G.; Cakaloglu, Y.; Tong, M. J.; Papatheodoridis, G.; Chen, Y.; Brown, N. A.; Albanis, E.; Galil, K.; Naoumov, N. V.; GLOBE Study Group (2009). "2-Year GLOBE trial results: Telbivudine is superior to lamivudine in patients with chronic hepatitis B". Gastroenterology. 136 (2): 486–495. doi:10.1053/j.gastro.2008.10.026. PMID 19027013.
- ↑ Naoumov, N. V. (2014). "Cyclophilin inhibition as potential therapy for liver diseases". Journal of Hepatology. 61 (5): 1166–1174. doi:10.1016/j.jhep.2014.07.008. PMID 25048953.
- ↑ Naoumov, N. V.; Brees, D.; Loeffler, J.; Chng, E.; Ren, Y.; Lopez, P.; Tai, D.; Lamle, S.; Sanyal, A. J. (2022). "Digital pathology with artificial intelligence analyses provides greater insights into treatment-induced fibrosis regression in NASH". Journal of Hepatology. 77 (5): 1399–1409. doi:10.1016/j.jhep.2022.06.018. PMID 35779659 Check
|pmid=value (help).
This article "Nikolai Naoumov" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Nikolai Naoumov. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
